Single-cell RNA sequencing analysis of lung cells in COVID-19 patients with diabetes, hypertension, and comorbid diabetes-hypertension
Xin Zhang, Xiaoqian Deng, Liangliang Zhang, Pengbo Wang, Xia Tong, Yan Mo, Yuansheng Zhang, Yan Zhang, Chunheng Mo, Lanlan Zhang · 2023
Read Single-cell RNA sequencing analysis of lung cells in COVID-19 patients with diabetes, hypertension, and comorbid diabetes-hypertension by Xin Zhang, Xiaoqian Deng, Liangliang Zhang, Pengbo Wang, Xia Tong, Yan Mo, Yuansheng Zhang, Yan Zhang, Chunheng Mo, Lanlan Zhang (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10748394.txt.
Description
Xin Zhang and co-authors published this study in 2023. It reads lung cells one by one in COVID-19 patients who also had diabetes, high blood pressure, or both. The lung is a known injury target in all three conditions. Blending single-cell data with bulk gene reads, the team hunted for drug targets and for doors the virus might use. Fibroblasts, the lung's scaffold cells, stood out.
Those cells grew more active in the combined conditions, a shift tied to worse lung function. Of the targets switched on in both diabetes and pressure cases, five sat in fibroblasts. A gene called KREMEN1, not the famous ACE2, looked like the activator's entry point. Two scar drugs were compared for this setting. One, nintedanib, seemed the better fit for patients showing fibrotic lung damage.
Catalog record
| CREATOR | Xin Zhang, Xiaoqian Deng, Liangliang Zhang, Pengbo Wang, Xia Tong, Yan Mo, Yuansheng Zhang, Yan Zhang, Chunheng Mo, Lanlan Zhang |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |